Tag Archives: Ultragenyx Pharmaceutical
The CBO & EVP of Ultragenyx Pharmaceutical (NASDAQ: RARE) is Selling Shares
Yesterday, the CBO & EVP of Ultragenyx Pharmaceutical (RARE – Research Report), Thomas Richard Kassberg, sold shares of RARE for $23.05K. Following Thomas Richard Kassberg’s last RARE Sell transaction on February 03, 2014, the stock climbed by 53.0%. In addition
The EVP, Finance of Ultragenyx Pharmaceutical (NASDAQ: RARE) is Selling Shares
Yesterday, the EVP, Finance of Ultragenyx Pharmaceutical (RARE – Research Report), Shalini Sharp, sold shares of RARE for $33K. In addition to Shalini Sharp, 10 other RARE executives reported Sell trades in the last month. Following Shalini Sharp’s last RARE
The CFO & EVP of Ultragenyx Pharmaceutical is Exercising Options
Yesterday it was reported that the CFO & EVP of Ultragenyx Pharmaceutical (RARE – Research Report), Shalini Sharp, exercised options to sell 14,378 RARE shares at $61.50 a share, for a total transaction value of $1.27M. Following Shalini Sharp’s last
A Director at Ultragenyx Pharmaceutical is Exercising Options
Yesterday it was reported that a Director at Ultragenyx Pharmaceutical (RARE – Research Report), Clay Siegall, exercised options to sell 34,750 RARE shares at $26.81 a share, for a total transaction value of $2.97M. See today’s analyst top recommended stocks
Ultragenyx Pharmaceutical (RARE) Receives a Hold from Credit Suisse
In a report released yesterday, Martin Auster from Credit Suisse maintained a Hold rating on Ultragenyx Pharmaceutical (RARE – Research Report), with a price target of $64.00. The company’s shares closed last Friday at $77.98. According to TipRanks.com, Auster is
J.P. Morgan Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
In a report issued on July 21, Cory Kasimov from J.P. Morgan maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report), with a price target of $84.00. The company’s shares closed last Monday at $81.42. According to TipRanks.com,
